Vaxcyte, Inc. (PCVX) vs Repligen Corporation (RGEN)
A side-by-side comparison of Vaxcyte, Inc. and Repligen Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PCVX
Vaxcyte, Inc.
$64.67HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
RGEN
Repligen Corporation
$178.10HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — PCVX vs RGEN
growth of $100 · dividends reinvested · last 6yPCVX +182.3% (+18.9%/yr)RGEN +62.2% (+8.4%/yr)PCVX compounded faster over this window
PCVX RGEN
PCVX vs RGEN: by the numbers
- •RGEN is the larger company ($10.05B vs $9.34B market cap).
- •RGEN is profitable (5.29% net margin) while PCVX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | PCVX | RGEN |
|---|---|---|
| P/E ratio | N/A | 243.97 |
| Forward P/E | N/A | 86.49 |
| P/S ratio | N/A | 12.80 |
| P/B ratio | 3.39 | 4.76 |
| EV / EBITDA | N/A | 68.26 |
| FCF yield | N/A | 1.10% |
Profitability
| Metric | PCVX | RGEN |
|---|---|---|
| Gross margin | 0.00% | 51.05% |
| Operating margin | 0.00% | 8.32% |
| Net margin | 0.00% | 5.29% |
| ROE | -38.59% | 1.97% |
| ROIC | -40.65% | 1.85% |
Growth (annualized)
| Metric | PCVX | RGEN |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 9.08% |
| EPS CAGR (5Y) | N/A | -5.26% |
| FCF CAGR (5Y) | N/A | 22.49% |
| Total return CAGR (5Y) | 25.08% | -6.86% |
Frequently asked
- Is PCVX or RGEN more profitable?
- RGEN runs the higher net margin — PCVX at 0.00% versus RGEN at 5.29%.
- How have PCVX and RGEN total returns compared?
- Over the past 5 years, PCVX delivered 25.08% and RGEN delivered -6.86% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Repligen P/E ratioVaxcyte ROERepligen ROEVaxcyte operating marginRepligen operating marginVaxcyte revenue growthRepligen revenue growthVaxcyte free cash flowRepligen free cash flow
Vaxcyte & Repligen appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.